Evaluating Neutralizing Antibodies in Hantavirus-Infected Patients Using Authentic Virus and Recombinant Vesicular Stomatitis Virus Systems
Abstract
:1. Introduction
2. Materials and Methods
2.1. Biosafety
2.2. Cells and Viruses
2.3. Patient Serum Sample Selection
2.4. IgG ELISA
2.5. Generation of VSV Chimeric Viruses
2.6. Neutralization Assays
3. Results
3.1. Neutralization Assays Using Monoclonal Antibodies and Archived Clinical Sera
3.2. Testing the Recombinant VSV-Based Hantavirus Surrogate System Using Neutralization Assays
3.3. Neutralization of VSV-SNV-ZsG Using Monoclonal Antibodies
3.4. Neutralization Potency of Archived Clinical Samples Using VSV-SNV-ZsG
3.5. Comparison of Neutralization Potency in Archived Clinical Samples Using VSV-SNV-ZsG and Authentic SNV Assays
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Macneil, A.; Nichol, S.T.; Spiropoulou, C.F. Hantavirus pulmonary syndrome. Virus Res. 2011, 162, 138–147. [Google Scholar] [CrossRef] [PubMed]
- Warner, B.M.; Dowhanik, S.; Audet, J.; Grolla, A.; Dick, D.; Strong, J.E.; Kobasa, D.; Lindsay, L.R.; Kobinger, G.; Feldmann, H.; et al. Hantavirus Cardiopulmonary Syndrome in Canada. Emerg. Infect. Dis. 2020, 26, 3020–3024. [Google Scholar] [CrossRef]
- Jonsson, C.B.; Figueiredo, L.T.; Vapalahti, O. A global perspective on hantavirus ecology, epidemiology, and disease. Clin. Microbiol. Rev. 2010, 23, 412–441. [Google Scholar] [CrossRef] [PubMed]
- Bausch, D.G.; Ksiazek, T.G. Viral hemorrhagic fevers including hantavirus pulmonary syndrome in the Americas. Clin. Lab. Med. 2002, 22, 981–1020, viii. [Google Scholar] [CrossRef] [PubMed]
- Bharadwaj, M.; Nofchissey, R.; Goade, D.; Koster, F.; Hjelle, B. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J. Infect. Dis. 2000, 182, 43–48. [Google Scholar] [CrossRef]
- MacNeil, A.; Comer, J.A.; Ksiazek, T.G.; Rollin, P.E. Sin Nombre virus-specific immunoglobulin M and G kinetics in hantavirus pulmonary syndrome and the role played by serologic responses in predicting disease outcome. J. Infect. Dis. 2010, 202, 242–246. [Google Scholar] [CrossRef]
- Valdivieso, F.; Vial, P.; Ferres, M.; Ye, C.; Goade, D.; Cuiza, A.; Hjelle, B. Neutralizing antibodies in survivors of Sin Nombre and Andes hantavirus infection. Emerg. Infect. Dis. 2006, 12, 166–168. [Google Scholar] [CrossRef]
- Ye, C.; Prescott, J.; Nofchissey, R.; Goade, D.; Hjelle, B. Neutralizing antibodies and Sin Nombre virus RNA after recovery from hantavirus cardiopulmonary syndrome. Emerg. Infect. Dis. 2004, 10, 478–482. [Google Scholar] [CrossRef]
- Cifuentes-Munoz, N.; Darlix, J.L.; Tischler, N.D. Development of a lentiviral vector system to study the role of the Andes virus glycoproteins. Virus Res. 2010, 153, 29–35. [Google Scholar] [CrossRef]
- Yu, L.; Bai, W.; Wu, X.; Zhang, L.; Zhang, L.; Li, P.; Wang, F.; Liu, Z.; Zhang, F.; Xu, Z. A recombinant pseudotyped lentivirus expressing the envelope glycoprotein of hantaan virus induced protective immunity in mice. Virol. J. 2013, 10, 301. [Google Scholar] [CrossRef]
- Ray, N.; Whidby, J.; Stewart, S.; Hooper, J.W.; Bertolotti-Ciarlet, A. Study of Andes virus entry and neutralization using a pseudovirion system. J. Virol. Methods 2010, 163, 416–423. [Google Scholar] [CrossRef] [PubMed]
- Engdahl, T.B.; Kuzmina, N.A.; Ronk, A.J.; Mire, C.E.; Hyde, M.A.; Kose, N.; Josleyn, M.D.; Sutton, R.E.; Mehta, A.; Wolters, R.M.; et al. Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection. Cell Rep. 2021, 35, 109086. [Google Scholar] [CrossRef] [PubMed]
- Vial, C.; Whitaker, A.; Wilhelm, J.; Ovalle, J.; Perez, R.; Valdivieso, F.; Ferres, M.; Martinez-Valdebenito, C.; Eisenhauer, P.; Mertz, G.J.; et al. Comparison of VSV Pseudovirus and Focus Reduction Neutralization Assays for Measurement of Anti-Andes orthohantavirus Neutralizing Antibodies in Patient Samples. Front. Cell Infect. Microbiol. 2020, 10, 444. [Google Scholar] [CrossRef]
- Petersen, J.; Drake, M.J.; Bruce, E.A.; Riblett, A.M.; Didigu, C.A.; Wilen, C.B.; Malani, N.; Male, F.; Lee, F.H.; Bushman, F.D.; et al. The major cellular sterol regulatory pathway is required for Andes virus infection. PLoS Pathog. 2014, 10, e1003911. [Google Scholar] [CrossRef]
- Engdahl, T.B.; Binshtein, E.; Brocato, R.L.; Kuzmina, N.A.; Principe, L.M.; Kwilas, S.A.; Kim, R.K.; Chapman, N.S.; Porter, M.S.; Guardado-Calvo, P.; et al. Antigenic mapping and functional characterization of human New World hantavirus neutralizing antibodies. Elife 2023, 12, e81743. [Google Scholar] [CrossRef]
- Stass, R.; Engdahl, T.B.; Chapman, N.S.; Wolters, R.M.; Handal, L.S.; Diaz, S.M.; Crowe, J.E., Jr.; Bowden, T.A. Mechanistic basis for potent neutralization of Sin Nombre hantavirus by a human monoclonal antibody. Nat. Microbiol. 2023, 8, 1293–1303. [Google Scholar] [CrossRef] [PubMed]
- Kleinfelter, L.M.; Jangra, R.K.; Jae, L.T.; Herbert, A.S.; Mittler, E.; Stiles, K.M.; Wirchnianski, A.S.; Kielian, M.; Brummelkamp, T.R.; Dye, J.M.; et al. Haploid Genetic Screen Reveals a Profound and Direct Dependence on Cholesterol for Hantavirus Membrane Fusion. mBio 2015, 6, e00801. [Google Scholar] [CrossRef]
- Shrivastava-Ranjan, P.; Jain, S.; Chatterjee, P.; Montgomery, J.M.; Flint, M.; Albarino, C.; Spiropoulou, C.F. Development of a novel minigenome and recombinant VSV expressing Seoul hantavirus glycoprotein-based assays to identify anti-hantavirus therapeutics. Antiviral Res. 2023, 214, 105619. [Google Scholar] [CrossRef]
- Knust, B.; Rollin, P.E. Twenty-year summary of surveillance for human hantavirus infections, United States. Emerg. Infect. Dis. 2013, 19, 1934–1937. [Google Scholar] [CrossRef]
- Shrivastava-Ranjan, P.; Lo, M.K.; Chatterjee, P.; Flint, M.; Nichol, S.T.; Montgomery, J.M.; O’Keefe, B.R.; Spiropoulou, C.F. Hantavirus Infection Is Inhibited by Griffithsin in Cell Culture. Front. Cell Infect. Microbiol. 2020, 10, 561502. [Google Scholar] [CrossRef]
- Alabi, A.; Kokou, K.; Mahmoudou, S.; Kavishna, R.; Nakka, S.S.; Rothenberger, S.; Musangomunei, F.P.; Olubiyi, B.F.; Bie-Ondo, J.C.; Kabwende, A.L.; et al. Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-DeltaG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambarene, Gabon. J. Infect. 2024, 89, 106237. [Google Scholar] [CrossRef] [PubMed]
- Brown, K.S.; Safronetz, D.; Marzi, A.; Ebihara, H.; Feldmann, H. Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus. J. Virol. 2011, 85, 12781–12791. [Google Scholar] [CrossRef] [PubMed]
- Lee, B.H.; Yoshimatsu, K.; Araki, K.; Okumura, M.; Nakamura, I.; Arikawa, J. A pseudotype vesicular stomatitis virus containing Hantaan virus envelope glycoproteins G1 and G2 as an alternative to hantavirus vaccine in mice. Vaccine 2006, 24, 2928–2934. [Google Scholar] [CrossRef]
- Prescott, J.; DeBuysscher, B.L.; Brown, K.S.; Feldmann, H. Long-term single-dose efficacy of a vesicular stomatitis virus-based Andes virus vaccine in Syrian hamsters. Viruses 2014, 6, 516–523. [Google Scholar] [CrossRef] [PubMed]
- Warner, B.M.; Stein, D.R.; Jangra, R.K.; Slough, M.M.; Sroga, P.; Sloan, A.; Frost, K.L.; Booth, S.; Chandran, K.; Safronetz, D. Vesicular Stomatitis Virus-Based Vaccines Provide Cross-Protection against Andes and Sin Nombre Viruses. Viruses 2019, 11, 645. [Google Scholar] [CrossRef]
- Marceau, J.; Safronetz, D.; Martellaro, C.; Marzi, A.; Rosenke, K.; Feldmann, H. Bivalent VSV Vectors Mediate Rapid and Potent Protection from Andes Virus Challenge in Hamsters. Viruses 2024, 16, 279. [Google Scholar] [CrossRef]
SNV-53 EC50 (ng/mL) | ANDV-44 EC50 (ng/mL) | |
---|---|---|
VSV-ZsG | >10,000 | >10,000 |
VSV-SNV-ZsG | 20.09 | 1104 |
VSV-ANDV-ZsG | 59.47 | 5.7 |
VSV-SEOV-ZsG | 391.1 | >10,000 |
Clinical Sample # | Neutralization Potency SNV/VSV-SNV-ZsG |
---|---|
Normal Human Sera | Low/Low |
9705418 | Low/Low |
SPR166 | Low/Low |
701976 | Low/Moderate |
703114 | High/Moderate |
9314091 | High/High |
703156 | High/High |
9426075 | High/High |
9414330 | High/High |
9317058 | High/High |
9311611 | High/High |
703113 | High/High |
703147 | High/High |
9318785 | High/High |
703139 | High/High |
703149 | High/High |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Shrivastava-Ranjan, P.; Kelly, J.A.; McMullan, L.K.; Cannon, D.; Morgan, L.; Chatterjee, P.; Jain, S.; Montgomery, J.M.; Flint, M.; Albariño, C.G.; et al. Evaluating Neutralizing Antibodies in Hantavirus-Infected Patients Using Authentic Virus and Recombinant Vesicular Stomatitis Virus Systems. Viruses 2025, 17, 723. https://doi.org/10.3390/v17050723
Shrivastava-Ranjan P, Kelly JA, McMullan LK, Cannon D, Morgan L, Chatterjee P, Jain S, Montgomery JM, Flint M, Albariño CG, et al. Evaluating Neutralizing Antibodies in Hantavirus-Infected Patients Using Authentic Virus and Recombinant Vesicular Stomatitis Virus Systems. Viruses. 2025; 17(5):723. https://doi.org/10.3390/v17050723
Chicago/Turabian StyleShrivastava-Ranjan, Punya, Jamie A. Kelly, Laura K. McMullan, Deborah Cannon, Laura Morgan, Payel Chatterjee, Shilpi Jain, Joel M. Montgomery, Mike Flint, César G. Albariño, and et al. 2025. "Evaluating Neutralizing Antibodies in Hantavirus-Infected Patients Using Authentic Virus and Recombinant Vesicular Stomatitis Virus Systems" Viruses 17, no. 5: 723. https://doi.org/10.3390/v17050723
APA StyleShrivastava-Ranjan, P., Kelly, J. A., McMullan, L. K., Cannon, D., Morgan, L., Chatterjee, P., Jain, S., Montgomery, J. M., Flint, M., Albariño, C. G., & Spiropoulou, C. F. (2025). Evaluating Neutralizing Antibodies in Hantavirus-Infected Patients Using Authentic Virus and Recombinant Vesicular Stomatitis Virus Systems. Viruses, 17(5), 723. https://doi.org/10.3390/v17050723